Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 8/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20874821 | 0.87 | MAPK1 (0.41) | CDK8JAK1JAK3TYK2MAPK1 | |
| SCHEMBL25523673 | 0.75 | MAPK1 (0.44) | CDK8MAPK1 | |
| Trifluoroacetic Acid SCHEMBL27742026 | 0.68 | KIT (0.37) | CDK8HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL28780341 | 0.66 | RIPK1 (0.40) | CDK8JAK3MAPK1HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL4751915 | 0.64 | RIPK1 (0.48) | CDK8JAK2 | |
| Trifluoroacetic Acid SCHEMBL30978135 | 0.63 | ADRB1 (0.50) | NPSR1HRH3 | |
| SCHEMBL29699518 | 0.63 | MAPK1 (0.48) | CDK8MAPK1 | |
| SCHEMBL10141177 | 0.63 | MAPK1 (0.48) | JAK1MAPK1JAK2 | |
| SCHEMBL12847281 | 0.63 | MAPK1 (0.71) | CDK8MAPK1 | |
| SCHEMBL2611061 | 0.62 | MAPK1 (0.55) | CDK8JAK1JAK3MAPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450436-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-11390634-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390634-B2 | Fused heterocyclic compound | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CDK8 143/4885JAK1 1193/4885JAK3 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.